In colorectal cancer, we and others observed that inhibiting Mitogen-Activated Protein Kinase Kinase (MEK) rapidly activates the epidermal growth factor receptor (EGFR), which synergistically enhances AKT signaling6,7. This evidence concerns the gene MAP2K7 and colorectal cancer.